Previous 10 | Next 10 |
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Postmodern Studio / Shutterstock.com Teladoc (NYSE: TDOC ) stock is on the move Thursday after getting an upgrade from SVB Securities . That upgrade has SVB Securities analysts boosting TDOC stock from a ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Connect world / Shutterstock.com Genprex (NASDAQ: GNPX ) stock is on the move Thursday after providing an update on a study of its diabetes treatment . That positive news comes from a trial of gene therap...
Genprex Announces Groundbreaking Data from Non-Human Primate Study Evaluating Novel Gene Therapy to Treat Type 1 Diabetes at 16th Annual International Conference on Advanced Technologies & Treatment for Diabetes 2023 Genprex Announces Groundbreaking Data from Non-Human Primate Study...
Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, has entered into an exclusive license agreement with the University of Pittsburgh. According to the announcement, the agreement gives Genprex a world...
Genprex Signs Exclusive License to Additional Diabetes Technology with the University of Pittsburgh PR Newswire Technologies Licensed from University of Pittsburgh May Have the Potential to Provide Long-Term Efficacy and to Change the Course of this Disease for the Million...
Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, announced that research evaluating the company’s gene therapy for type 1 diabetes will be presented at the 16th International Conference on Ad...
Genprex Announces Selection of Preclinical Data for Oral Presentation at 16th International Conference on Advanced Technologies & Treatments for Diabetes Genprex Announces Selection of Preclinical Data for Oral Presentation at 16th International Conference on Advanced Technologies &...
Genprex Strengthens Diabetes Gene Therapy Program with License of Additional Technology from University of Pittsburgh PR Newswire Technology for modulating autoimmunity expands intellectual property portfolio AUSTIN , Texas , Dec. 15, 2022 /PRNewswire/ --...
Genprex ( NASDAQ: GNPX ) said a Safety Review Committee (SRC) approved continuation to the third and final group in the dose escalation phase 1 part of a phase 1/2 trial. The study, dubbed Acclaim-1, is evaluating Reqorsa in combination with in combination with AstraZen...
Genprex Receives Safety Review Committee Approval to Proceed to Final Cohort in Acclaim-1 Phase 1 Dose Escalation Trial of REQORSA® in Combination with Tagrisso® in Advanced Non-Small Cell Lung Cancer PR Newswire Recommendation to Advance to Increased Dose in Third a...
News, Short Squeeze, Breakout and More Instantly...
Genprex Issues Stockholder Letter and Provides 2024 Corporate Update PR Newswire Company Achieves Multiple Clinical Development Milestones in 2024 Patient Treatment Continues in Three Lung Cancer Clinical Trials AUSTIN, Texas , June 27, 2024 /PRNe...
Genprex to Present at the 2024 BIO International Convention PR Newswire Presentation to Highlight the Company's Gene Therapies for Cancer and Diabetes AUSTIN, Texas , May 30, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: ...